ESC 365
Menu
Home
Search
Live & Upcoming Events
About
Create an account
Sign in
Back
ESC Premium Access
Oral anticoagulants : news from large trials and registries
Event:
ESC Congress 2018
Topic:
Anticoagulants
Session type:
Moderated Posters
Date:
28 August 2018
Time:
15:50 - 16:40
Congress Session
0
6
presentations
in this session
Real-world clinical data of atrial fibrillation patients treated with direct oral anticoagulants in combination with or without antiplatelet therapy
Speaker:
Doctor R. Amiya (Osaka, JP)
Access
Abstract
Slides
0
Characterization of major and clinically relevant non-major bleeding in the APEX trial
Speaker:
Miss M. Yee (Boston, US)
Access
Abstract
Slides
0
Increased major bleeding risk with use of topical miconazole agents among users of oral anticoagulation: A population-level safety study
Speaker:
Doctor M. Lamberts (Copenhagen, DK)
Access
Abstract
Slides
0
Differences between hospitalised vs. outpatient management amongst european patients with atrial fibrillation: the EORP-AF general long-term registry
Speaker:
Doctor M. Proietti (Milan, IT)
Access
Abstract
Slides
0
Comparison of P2Y12 inhibitors in atrial fibrillation patients treated by dual-antiplatelet therapy without oral anticoagulant after acute myocardial infarction with percutaneous coronary intervention
Speaker:
Professor H. Jeong (Gwangju, KR)
Access
Abstract
Slides
0
Oral anticoagulants in patients with atrial fibrillation and non-mechanical heart valve disease
Speaker:
Mr J. Strange (Copenhagen, DK)
Access
Abstract
Slides
0
6
speakers
from this session
Doctor Ryohei Amiya
Osaka University, Osaka (Japan)
0
follower
Miss Megan Yee
, Boston (United States of America)
0
follower
Doctor Morten Lamberts
Herlev and Gentofte Hospital, Copenhagen (Denmark)
0
follower
Doctor Marco Proietti
University of Milan, Milan (Italy)
6
presentations
0
follower
Professor Hyung Ki Jeong
Chonnam National University Hospital, Gwangju (Korea (Republic of))
0
follower
Mr Jarl Emanuel Strange
Herlev and Gentofte University Hospital, Copenhagen (Denmark)
0
follower
This platform is supported by